Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.

Apogee Therapeutics on Wednesday posted favorable results from a mid-stage trial of its experimental eczema drug and secured a financing deal worth ​up to $1.3 billion with Blackstone Life Sciences.

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, ...

Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences (BXLS) as the ...

SINGAPORE: At the height of her eczema flare, Ms Chloe Ng struggled to hold a pen or carry a spoon as her fingers were covered in open wounds. For years, she cycled through treatments, including oral ...

New long-term data show Eli Lilly and Company's Ebglyss (lebrikizumab-lbkz) delivered durable skin clearance?and?relief from persistent?itch for up to four years for patients with moderate-to-severe ...

Eli Lilly (LLY) announced late-stage trial data for Ebglyss, its FDA-approved therapy for atopic dermatitis (eczema), on Friday, indicating that the once-monthly injectable led to a durable treatment ...

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin ...

Please provide your email address to receive an email when new articles are posted on . A higher proportion of participants receiving Ebglyss achieved the coprimary and secondary endpoints vs. placebo ...

In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of ...

“2025 was another important year for Almirall as we continue to deliver against our sustained growth trajectory and further expand our leadership in medical dermatology. Another year of double-digit ...